Tokyo, Sept. 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058428) titled 'Additive effect of P2X3 inhibitor, gefapixant, on azelastin for refractory atopic cough' on Sept. 30.
Study Type:
Observational
Primary Sponsor:
Institute - Respiratory and Allergy Medicine, Kansai Medial University
Condition:
Condition - Atopic cough
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - A retrospective clinical study will be conducted to evaluate the efficacy of gefapixant, a P2X3 inhibitor for the new treatment of chronic cough, in patients with refractory atopic cough in real clinical practice.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
<
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Refractory atopic cough
Key exclusion criteria - (1) Patients with unstable comorbidities
(2) Other patients deemed inappropriate as research subjects by the principal investigator
Target Size - 30
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2022 Year 04 Month 01 Day
Date of IRB - 2026 Year 07 Month 10 Day
Anticipated trial start date - 2022 Year 04 Month 01 Day
Last follow-up date - 2025 Year 08 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066806
Disclaimer: Curated by HT Syndication.
